PHX

0.00%

4.7¢ pharmx technologies limited

Ann: Trading Update-COO.AX, page-29

First 29 Last

Share
Profile

Follow
roboshan

2,481 Posts.

173

15/08/16

09:53

Post #: 18516877
Share

Originally posted by roboshan ↑

"take a longer look"

Share price is probably about where you expect it to be given the decline in revenue, recent one off additional tax liability and illiquidity of this stock. There really hasn't been any encouraging signs for at least three years. Surely the management of the company over past years have to take some responsibility for not being able to find growth drivers but they have been like many other businesses with declining revenue been operating in an tough environment. Maintaining any profitability at all is perhaps seen as a positive. On analysis of what is occurring currently within retail pharmacy in particular it does not give me much optimism for any significant organic growth.

On a longer look though, shareholders still have a company with no debt, $12 million in cash, an underlying profit (before the recent tax bill shock) of about $2m and a current market capitalisation of $20m. This alone is perhaps probably not enough incentive to invest in Corum. I think to see demand driving up the share price it will need more than just a boring old balance sheet that most companies would die for. The spark that is needed is the long awaited synergistic acquisition.

I still favour the acquisition of another pharmacy software company. If Corum are finding it tough given their scale/market share so are the others. It is also their area of expertise. Which company should they target. Many years ago they acquired Amfac from Symbion and perhaps then paid too much at a time when it was seemingly all blue sky. Perhaps it is time to have discussions with Symbion again and take a close look at their MINFOS software business (number 3 in the terms of market share behind FRED and LOTS). Certainly no harm in talking to them as they could very well be close to being marginal given their smaller market share and they may be happy to divest and have their IT department focussed on other core areas.

Tough times often create opportunity!

Expand

Just to clarify - The Amfac acquisition was made pre Symbion days. The deal was with Faulding prior to their acquisition by Mayne, then Zuellig and now is part of the diversified EBOS stable.

COO Price at posting: 7.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 1 more message in this thread...

First 29 Last

Add PHX (ASX) to my watchlist

(20min delay)
Last 4.7¢		Change 0.000(0.00%)		Mkt cap ! $28.12M

Open	High	Low	Value	Volume
4.7¢	4.7¢	4.7¢	$940	20K

Buyers (Bids)

No.	Vol.	Price($)
1	83300	4.4¢

Sellers (Offers)

Price($)	Vol.	No.
4.7¢	174999	3

View Market Depth

No.	Vol.	Price($)
1	83300	0.044
1	78187	0.043
1	13940	0.042
1	137600	0.041
1	165000	0.040

Price($)	Vol.	No.
0.047	174999	3
0.050	324438	3
0.055	555000	3
0.057	500000	1
0.080	50000	1

Last trade - 10.06am 04/10/2024 (20 minute delay)

PHX (ASX) Chart

Ann: Trading Update-COO.AX, page-29

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Update-COO.AX, page-29

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News